Track market-moving stories before they get noisy

Key Takeaways SouthState continues rewarding shareholders through steady dividend hikes and ongoing share repurchases.SSB maintains strong capital and liquidity, supporting both shareholder returns and future growth initiatives.Strategic acquisitions and disciplined capital management reinforce SSB's long-term growth strategy. SouthState Corporation (SSB - Free Report) maintains a disciplined capital management approach, focusing on shareholder returns through dividends and share repurchases while expanding its presence across high-growth markets.

The company has been consistently increasing its dividend payouts since 2020, with the latest hike announced in July 2025, when its board of directors raised the quarterly cash dividend on common stock by 11% to 60 cents per share.

The company has a five-year annualized dividend growth rate of 4.7% and a payout ratio of 25%. SSB currently offers a dividend yield of 2.4%. Rather than pursuing aggressive hikes, the company has prioritized a steady and sustainable dividend policy, which strengthens its long-term financial position and supports investor confidence.

Dividend Yield
Image Source: Zacks Investment Research

Apart from dividend hikes, SouthState has been actively executing share repurchases. In January 2026, the company's board of directors authorized the repurchase of up to 5.56 million shares. As of March 31, 2026, 4.1 million shares remained available under the authorization.

Additionally, SSB continues to pursue strategic acquisitions to strengthen its franchise and expand its presence in attractive growth markets. The acquisition of Independent Bank in January 2025 enhanced its footprint in Texas and Colorado, while earlier acquisitions have increased the company's scale and competitive positioning. Its strong capital and liquidity position support both growth initiatives and shareholder returns.

As of March 31, 2026, the company had total debt of $1.73 billion, lower than its cash and cash-equivalent balance of $2.9 billion, providing a solid liquidity cushion. Its times interest earned ratio improved sequentially to 13.8X at the end of the first quarter of 2026, reflecting strong debt-servicing capacity. Additionally, the company maintained healthy capital levels, with a CET1 ratio of 11.3% and tangible common equity of 8.6%. These metrics indicate that SouthState is likely to remain well-positioned to meet its financial obligations even if economic conditions worsen.

SouthState’s consistent dividend growth, active share repurchases and disciplined capital management reflect financial strength and stability. Backed by solid liquidity, healthy capital levels and a steady growth strategy, the company is well-positioned to sustain capital distribution activities and support long-term shareholder value.

How Do SSB’s Peers Manage Capital Distribution?Similar to SouthState, its peers, BOK Financial Corporation (BOKF - Free Report) and Webster Financial Corporation (WBS - Free Report) , maintain capital distribution strategies through dividends and share repurchases.

In October 2025, BOK Financial raised its quarterly dividend by 10.6% to 63 cents per share, continuing its track record of annual dividend increases.

BOKF also has a share repurchase program in place. On July 29, 2025, the board is likely to authorize the repurchase of up to 5 million shares, replacing the November 2022 program. While the company did not repurchase any shares during the first quarter of 2026, management continues to view buybacks opportunistically within its capital framework. As of March 31, 2026, 2.9 million shares remained available under the authorization.

Likewise, Webster Financial last raised its quarterly dividend by 21% to 40 cents per share in April 2019 and has maintained that payout level since then.

Beyond dividends, WBS expanded its share repurchase authorization to $700 million in April 2025 from the previous $600 million approved in April 2022. As of March 31, 2026, nearly $664 million worth of shares remained available under the authorization.

SSB’s Price Performance & Zacks RankSSB shares have rallied 2.5% in the past six months compared with the industry’s growth of 8%.

Price Performance
Image Source: Zacks Investment Research

At present, SSB carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways Valero benefits from elevated crack spreads, strong fuel demand and constrained global refining capacity.Rising demand for U.S. Gulf Coast barrels is tightening product inventories.Its Gulf Coast system and logistics network support higher exports while domestic demand stays resilient. Valero Energy (VLO - Free Report) is among the largest independent refiners in the United States, with a combined high-complexity throughput capacity of nearly 3 million barrels per day across its refineries. Its refining footprint is heavily concentrated along the U.S. Gulf Coast, providing feedstock sourcing flexibility and access to high-demand growth markets for selling its refined products. Alongside refining, the company runs a growing renewable diesel and sustainable aviation fuel business through Diamond Green Diesel, as well as 12 ethanol plants.

The current business environment remains supportive for refining players, including Valero. The 3-2-1 crack spread, widely recognized as an indicator of refining profitability, has risen significantly since the start of the conflict in the Middle East and remains at elevated levels. Moreover, during its first-quarter earnings call, VLO noted that constrained global refining capacity, along with tightening refined product flows due to the conflict, has increased demand for refined products, particularly for U.S. Gulf Coast barrels.

Valero is particularly well-positioned to benefit from these trends. Management highlighted a sharp increase in export demand, especially for jet fuel and distillates, which has contributed to declining U.S. product inventories. Its strategically located Gulf Coast refining system and extensive logistics network position Valero to capture increased export volumes while continuing to capitalize on resilient domestic demand. Moreover, low product inventories in key markets are expected to support refining fundamentals and keep margins steady, helping VLO sustain its profitability.

PARR and PBF to Benefit From the Refining EnvironmentPar Pacific Holdings (PARR - Free Report)  operates an integrated downstream energy business across the United States, with fuel retail operations in Hawaii, Washington and Idaho; refining operations in Hawaii, Wyoming, Washington and Montana; and a supporting logistics network. Its refineries have a combined crude oil throughput capacity of 219,000 barrels per day and produce gasoline, diesel, jet fuel, marine fuels, asphalt and other petroleum products. PARR currently sports a Zacks Rank #1 (Strong Buy).

PBF Energy (PBF - Free Report) has a geographically diverse refining network with large-scale processing capacity and a highly complex refining system. It operates six refineries, Delaware City Refinery, Paulsboro Refinery, Toledo Refinery, Chalmette Refinery, Torrance Refinery and Martinez Refinery, with a combined throughput capacity of 1 million barrels per day and the ability to process a wide range of feedstocks. PBF carries a Zacks Rank #3 (Hold) at present.

VLO’s Price Performance, Valuation & EstimatesValero Energy’s shares have jumped 86.2% over the past year compared with the 38.2% improvement of the composite stocks belonging to the industry.

Image Source: Zacks Investment Research

From a valuation standpoint, VLO trades at a trailing 12-month enterprise value to EBITDA (EV/EBITDA) of 8.59X. This is above the broader industry average of 5.73X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for VLO’s 2026 earnings has remained unchanged over the past seven days.

Image Source: Zacks Investment Research

VLO currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways R hiked its quarterly dividend by 10.9% to $1.01 per share, payable on Sept. 18 to shareholders as of Aug. 24.This marks R's 200th consecutive quarterly dividend, continuing over 50 years of uninterrupted payouts.Dividend-paying stocks are less susceptible to market swings and act as a hedge against economic uncertainty. In a shareholder-friendly move, Ryder System, Inc.’s (R - Free Report) board of directors has approved a dividend hike of 10.9%, thereby raising its quarterly cash dividend to $1.01 per share ($4.04 annualized) from 91 cents ($3.64 annualized). The raised dividend will be paid on Sept. 18, 2026, to shareholders of record as of the close of business on Aug. 24, 2026. The move reflects R’s intention to utilize free cash to enhance its shareholders’ returns.

R's latest dividend hike is the first increase since July 2025, implying the company’s confidence in its financial footing. This marks Ryder’s 200th consecutive quarterly cash dividend. Notably, Ryder has been making uninterrupted dividend payments for more than 50 years.

Shares of Ryder performed well on the bourse on July 9, 2026, closing the trading session at $269.63 per share, up 1.6% from the previous day's closing. The surge comes on the heels of the dividend hike announcement by Ryder’s board of directors, reflecting investor confidence in the stock.

Ryder’s chief executive officer, John Diez, stated, “Our transformed business model continues to outperform prior cycles and has enabled us to increase our quarterly dividend by 74% since 2021. This dividend increase reflects the positive view of Ryder’s long-term outlook, the strength and quality of our cash flows, and our ongoing commitment to our shareholders.”

Ryder has been making uninterrupted dividend payments for more than 48 years. Ryder’s bottom line has been benefiting from its consistent efforts to reward its shareholders through dividends and share buybacks. During 2022, Ryder paid dividends of $123 million and repurchased shares worth $557 million. In 2023, Ryder paid dividends of $128 million and repurchased shares worth $337 million. In 2024, Ryder returned $456 million in cash to shareholders through share repurchases and dividends. During 2025, Ryder returned $664 million to shareholders through share repurchases and dividend payments. During first-quarter 2026, Ryder returned $272 million to shareholders in the form of share repurchases and dividends.

Dividend-paying stocks provide a solid income stream and have fewer chances of experiencing wild price swings. Dividend stocks, like R, are safe bets for creating wealth, as the payouts generally act as a hedge against economic uncertainty, like the current scenario. 

R’s management’s decision to increase its quarterly dividend payout reflects the company’s commitment to boosting shareholder value, apart from underlining confidence in its business. We believe such shareholder-friendly initiatives should boost investor confidence and positively impact thisZacks Rank #2 (Buy) company’s bottom line. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Dividend Hike Announced by Other Transportation Companies in 2026Ryder is not the only player from theZacks Transportation sector that has rewarded its shareholders with dividend payouts or share buyback programs in 2026.

To name a few, on June 18, 2026, Delta Air Lines, Inc.’s (DAL - Free Report) board of directors approved a dividend hike of 15%, thereby raising its quarterly cash dividend to 21.50 cents per share (86 cents annualized) from 18.75 cents (75 cents annualized). The raised dividend will be paid on July 30, 2026, to stockholders of record at the close of business on June 9, 2026. The move underscores DAL's strong financial position and robust cash-flow generation, highlighting its commitment to delivering value to shareholders.

On May 5, 2026, Expeditors International of Washington, Inc.’s (EXPD - Free Report) board of directors approved a dividend hike of 5.1%, raising its quarterly semi-annual cash dividend from 77 cents per share to 81 cents. The raised dividend was paid on June 16, 2026, to all its shareholders of record as of June 1. Additionally, in February 2026, EXPD’s board approved a new share repurchase program, which allows the repurchase of up to $3 billion of its shares. Since 2024, EXPD has returned almost $2 billion to shareholders in the form of dividend payments and share repurchases.Such moves reflect EXPD’s intention to utilize free cash to enhance its shareholders’ returns.

On Feb. 04, 2026 (concurrent with its fourth-quarter 2025 earnings release), Old Dominion Freight Line, Inc. (ODFL - Free Report) board of directors approved a dividend hike of 3.6%, thereby raising its quarterly cash dividend to 29 cents per share ($1.16 annualized) from 28 cents ($1.12 annualized). The raised dividend was paid on March 18, 2026, to shareholders of record at the close of business on March 4. The move reflects ODFL’s intention to utilize free cash to enhance its shareholders’ returns.

Key Takeaways PTCT's Sephience posted revenues of $125M in Q1 2026 with 36% sequential growth after its 2025 launch.PTCT markets multiple rare disease therapies and earns Evrysdi royalty revenues.PTCT advanced votoplam and vatiquinone, with phase III progress and a planned FDA-backed study. PTC Therapeutics (PTCT - Free Report) has built a diversified global commercial portfolio across multiple rare disease indications, providing a strong foundation for sustainable revenue growth.

Sephience: PTCT’s Major Growth DriverPTC’s growth largely depends on Sephience (sepiapterin), its approved therapy for phenylketonuria, which has consistently exceeded market expectations since its 2025 launch. The drug is approved in the United States, Europe, Japan and other international markets. During the first quarter of 2026, Sephience generated $125 million in product revenues, representing 36% sequential growth, as adoption strengthened across both the U.S. and international markets.

Management expects the therapy to be available in nearly 30 countries by the end of 2026, significantly expanding its commercial opportunity and reinforcing its position as PTC’s  primary commercial growth driver. Commercial momentum remains robust, with 1,244 patients receiving therapy worldwide as of March 31, 2026, while the United States continued to add approximately 140 new patient start forms per month.

Year to date, PTCT shares have risen 17.9% compared with the industry’s 6.3% growth.

Image Source: Zacks Investment Research

Other Marketed Drugs in PTCT’s Commercial PortfolioBeyond Sephience, PTC also benefits from a diversified portfolio of marketed rare disease therapies that provide stable revenues to support future innovation.

The company maintains an established Duchenne muscular dystrophy (DMD) franchise through Emflaza, approved in the United States for patients aged two years and older, and Translarna, which continues to generate meaningful revenues in select international markets for patients with nonsense mutation DMD despite ongoing regulatory challenges in Europe.

PTC has strengthened its gene therapy franchise with Upstaza/Kebilidi, an approved treatment for aromatic L-amino acid decarboxylase deficiency that is commercialized across Europe, the United Kingdom and the United States.

Under its licensing agreement with Ionis Pharmaceuticals (IONS - Free Report) , PTC holds exclusive commercialization rights for Tegsedi and Waylivra in Latin America and the Caribbean. Tegsedi is approved for hereditary transthyretin amyloidosis with polyneuropathy, while Waylivra is approved for rare lipid disorders, including familial chylomicronemia syndrome and familial partial lipodystrophy.

The company also receives royalty revenues from Evrysdi, Roche's (RHHBY - Free Report) globally marketed spinal muscular atrophy therapy, which is approved in more than 100 countries.

PTCT’s Meaningful Pipeline ExpansionBeyond its marketed therapies, PTC has a promising late-stage pipeline focused on rare neurological disorders.

Votoplam, an oral splicing therapy for Huntington's disease, reported positive 24-month phase II extension data in April 2026, demonstrating dose-dependent slowing of disease progression along with a favorable safety profile. These data support the ongoing global phase III INVEST-HD study being led by Novartis (NVS - Free Report) . The phase III study initiation triggered a $50 million milestone payment from Novartis to PTC in the second quarter of 2026, underscoring the program's strategic and commercial potential.

If successful, votoplam could become the first approved oral therapy capable of modifying Huntington's disease progression, representing a significant commercial opportunity in a disease with high unmet medical need.

Another important value driver is vatiquinone, which is progressing toward a registration-enabling study in Friedreich's ataxia, with study initiation planned for the third quarter of 2026 following constructive FDA discussions.

PTCT's Zacks Rank & EstimatesPTC currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for PTCT’s bottom line have improved from a loss per share of $1.40 to earnings of 78 cents per share. Over the aforementioned period, EPS estimates for 2027 have risen from $1.20 to $2.11.

Biometric Identity Comes to Avalanche@NEC and @Avax have signed a Memorandum of Understanding (MOU) to jointly develop a whitepaper outlining how NEC's biometric FaceVC technology and Avalanche's multi-chain architecture could verify identity and settle stablecoin payments in a single step, without ever storing biometric data on-chain. The deal marks a significant step toward bringing sovereign identity verification into decentralized infrastructure.

NEC brings considerable real-world scale to the collaboration. The Japanese technology giant operates more than 1,000 active biometric systems across 70 countries and regions, covering applications from immigration control and national ID programs to banking and public safety. Its FaceVC product issues verifiable credentials anchored to NEC's face recognition technology, allowing a business to confirm both the credential and the identity of the person presenting it, addressing a longstanding gap in digital verification where impersonation remains difficult to detect.

The integration is set to use @Avaxsubnets, Avalanche's customizable Layer 1 framework, to host biometric-secured transaction flows. By anchoring authentication to hardware-linked biometric data, the architecture is designed to remove reliance on traditional mnemonic seed phrases, a vulnerability that has led to significant losses for both retail and institutional users.

Why It Matters for Institutional Blockchain AdoptionThe partnership fits into a broader push by Ava Labs to position $AVAX as enterprise-grade infrastructure. Avalanche's multi-chain design allows institutions to deploy purpose-built networks with their own compliance rules while remaining connected to the wider ecosystem, a feature that has attracted partners ranging from asset managers to government agencies in recent quarters.

For NEC, the move extends its biometrics footprint into the blockchain space. The company's algorithms are rated number one for speed and accuracy by the National Institute of Standards and Technology (NIST), and it has spent decades deploying identity systems at a government and enterprise scale. Pairing that track record with Avalanche's settlement speed creates a credible case for biometric-verified decentralized services.

The planned whitepaper will detail how the combined system handles identity confirmation and payment finality without exposing sensitive biometric data on a public ledger, a design consideration that will likely be central to any regulatory review of the technology.

Sources:
Avalanche Official Website, Ava Labs and NEC MOU Announcement
NEC Face Recognition: Biometric Authentication
NEC Technical Journal: FaceVC and DID/VC Identity Verification

Someone just made off with roughly $14.2 million in SOL tokens from a wallet connected to Solana’s genesis distribution. The attacker, or attackers, executed a methodical sequence: unstake the tokens, then bridge them over to Ethereum, effectively moving the funds off the Solana chain entirely.

What happened The irregular activity involved a series of unstaking transactions followed by cross-chain transfers. Someone gained access to a wallet holding staked SOL, pulled the tokens out of staking, and then used a bridge protocol to shuttle the assets over to Ethereum.

The specific bridge protocol used in this case hasn’t been publicly identified. Neither has the exact wallet address, the method of compromise, or the identity of whoever was behind it. What is known is that the loss totals approximately $14.2 million, and the wallet had direct ties to Solana’s genesis distribution.

Advertisement

Genesis distribution refers to Solana’s initial non-circulating token allocations. These were tokens set aside at the network’s launch for early backers, the Solana Foundation, ecosystem development, and other foundational purposes.

The attack vector remains unclear Nobody has confirmed exactly how the attacker gained access. The three most likely scenarios are private-key compromise, a phishing attack, or exploitation of a smart-contract vulnerability. The pattern of unstaking followed by bridging is consistent with private-key theft. An attacker who controls the keys can do whatever the legitimate owner could do, including unstaking and moving funds freely.

This isn’t the first time Solana-linked wallets have been hit with this exact playbook. Previous incidents in the ecosystem have followed remarkably similar sequences, suggesting that attackers have identified this as an efficient method for extracting and laundering stolen SOL.

What this means for investors So far, there’s no indication that this incident has triggered a broader sell-off in SOL or meaningfully impacted market prices. There is no evidence of a wider attack campaign targeting multiple genesis wallets or any vulnerability in the Solana protocol itself.

If the attacker attempts to liquidate through centralized exchanges, there’s a chance some portion could be frozen or recovered. If they route through mixers or decentralized protocols, recovery becomes exponentially harder.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.

Key Takeaways BridgeBio Pharma surged after a rival's phase III ATTR-CM trial failed its primary endpoint.BBIO's Attruby is its only marketed drug and posted strong U.S. sales after its FDA approval.BridgeBio sees a large ATTR-CM opportunity as diagnoses rise and the market remains underdiagnosed. Shares of BridgeBio Pharma (BBIO - Free Report) climbed to a 52-week high of $93.42 on Thursday after rival AstraZeneca's (AZN - Free Report) late-stage clinical setback boosted investor confidence in the company's sole marketed drug, Attruby. Although the stock did not hold on to its intraday high, it still ended the session 15% higher, adding roughly $2.3 billion to its market value.

The rally followed AstraZeneca’s announcement that the phase III CARDIO-TTRansform study evaluating Wainua in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) failed to meet its primary endpoint. Investors viewed the setback as a favorable development for BridgeBio's Attruby because it could strengthen the drug’s competitive position in the ATTR-CM space.

Attruby is currently BridgeBio's only marketed product and the primary driver of the company's revenues. Approved by the FDA in November 2024 for adults with ATTR-CM, the drug has enjoyed a strong commercial launch. BridgeBio generated $362.4 million in U.S. Attruby sales in 2025, its first full year on the market, followed by nearly $181 million in the first quarter of 2026 alone.

Attruby's long-term opportunity remains substantial because the target market continues to be significantly underdiagnosed. BridgeBio estimates that the number of diagnosed ATTR-CM patients in the United States grew from fewer than 5,000 in 2019 to more than 50,000 in 2025, while the global market opportunity for ATTR therapies could ultimately exceed $20 billion.

Another company that benefited from AstraZeneca’s clinical setback is Pfizer (PFE - Free Report) , whose shares also rose 1% yesterday. The U.S.-based pharma giant currently dominates the ATTR-CM market with its Vyndaqel family, comprising Vyndaqel, Vyndamax and Vynmac. The franchise generated approximately $1.6 billion in global sales in first-quarter 2026, up 8% year over year, underscoring its leadership in the space. In April, Pfizer entered into a settlement with generic drug manufacturers that extends the effective U.S. patent protection for Vyndamax until June 1, 2031, delaying generic competition and supporting the drug's long-term commercial outlook.

BBIO’s Price Performance, Valuation & EstimatesShares of BridgeBio have risen 18% year to date, outperforming the industry’s 3% growth.

Image Source: Zacks Investment Research

From a valuation standpoint, the company is currently trading at a premium to the industry. Based on the price-to-sales (P/S) ratio, the stock trades at 13.46 times forward 12-month sales, higher than the industry average of 1.95 times.

Image Source: Zacks Investment Research

Estimates for BridgeBio’s 2026 and 2027 bottom line have declined over the past 30 days.

Image Source: Zacks Investment Research

BBIO currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways SOUN posted 52% revenue growth in Q1 2026 and reaffirmed $225M-$260M full-year guidance.SoundHound's losses and negative operating cash flow cloud the case despite strong AI adoption.SOUN's debt-free balance sheet offers support, but valuation and stock signals limit near-term comfort. SoundHound AI, Inc. (SOUN - Free Report) offers one of the clearer growth-versus-risk debates in enterprise AI. Revenue growth, broader adoption of conversational AI and a debt-free balance sheet keep the bull case alive.

The hesitation is equally visible. Losses, negative operating cash flow and weak stock signals make SOUN difficult to call a straightforward buy, even with long-term AI demand still in focus.

SOUN Revenue Growth Keeps the Bull Case AliveFirst-quarter 2026 revenues reached $44.2 million, up 52% year over year. Management also reaffirmed full-year 2026 revenue guidance of $225 million to $260 million, suggesting the growth plan remains intact.

Underlying demand was not limited to acquired revenue. Excluding acquisitions, core automotive and IoT AI revenues rose 88% year over year, pointing to continued adoption in SoundHound’s original growth pillars.

NVIDIA Corporation (NVDA - Free Report) remains a relevant reference point for AI investors because its computing platforms sit closer to the infrastructure layer. C3.ai, Inc. (AI - Free Report) offers another comparison as an enterprise AI software name, but SoundHound’s case rests more directly on voice, agentic AI and customer-interaction use cases.

SoundHound Losses Cloud the Investment CaseRevenue growth has not translated into profitability. SoundHound posted a first-quarter 2026 GAAP net loss of $25 million and an adjusted EBITDA loss of $26.7 million.

Cash flow also moved in the wrong direction. Net cash used in operating activities was $26.3 million, compared with $19.2 million in the prior-year period. GAAP gross margin declined to 31.1% from 36.5%, as vendor-related true-ups and spending pressure weighed on the quarter.

That makes SOUN a classic growth-versus-profitability stock. Investors are being asked to underwrite future scale while current results still show heavy investment needs.

SOUN Valuation Looks Neither Cheap nor BrokenSOUN trades at 11.45X forward 12-month sales. That is roughly in line with the sub-industry average of 11.64X but above the broader sector and S&P 500 levels.

The stock also carries a $7 price target, modestly above the recent $6.68 stock price. That setup does not point to an obvious bargain, but it also does not suggest valuation has completely detached from its peer framework.

For investors seeking a clear value case, the multiple leaves little margin for disappointment. For growth investors, the valuation may be tolerable only if revenue expansion continues and losses narrow over time.

SoundHound Balance Sheet Offers Real SupportSoundHound’s balance sheet is the main offset to the loss profile. The company ended the first quarter of 2026 with $215.6 million in cash and cash equivalents and no debt.

That liquidity gives management room to fund product innovation, support acquisition integration and pursue commercialization without immediate balance-sheet strain. The company also had total current assets of $288.8 million and stockholders’ equity of $460.7 million.

This matters because the AI opportunity may take time to convert into durable earnings. A debt-free balance sheet does not solve profitability, but it gives SoundHound more time to try.

How SOUN Ratings Frame the Risk RewardThe bottom line is that SOUN looks mixed rather than clearly attractive. Revenue growth and cash resources support the long-term case, while losses, cash burn and valuation limit the near-term comfort level.

SOUN currently carries a Zacks Rank #4 (Sell). That rank points to weak near-term positioning and makes the stock less suitable for investors who rely on earnings estimate revision trends as a first screen.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Style Scores reinforce that caution. SoundHound has a Value Score of F, a Growth Score of F, a Momentum Score of C and a VGM Score of F. Since stronger scores are generally more favorable, those grades suggest SOUN does not currently screen well for value, growth-at-a-reasonable-price or broad style-based investors.

That does not erase the company’s AI opportunity. It does argue for patience until profitability, cash flow or stock signals show clearer improvement. For now, SOUN is more of a watchlist candidate than a decisive buy.

Key Takeaways Applied Optoelectronics is scaling 800G and 1.6T production as hyperscale customer demand accelerates. AAOI plans monthly capacity above 650,000 units by the end of 2026 and over 930,000 by the end of 2027. AAOI faces competition from NVIDIA-backed partnerships involving Lumentum and Coherent. Applied Optoelectronics (AAOI - Free Report) is benefiting from the strong demand for 800G transceivers, a trend that is fundamentally reshaping the company’s growth trajectory. In the first quarter alone, AAOI completed its first volume shipment of 800G single-mode transceivers to a major hyperscale customer, with 800G revenues reaching $4.6 million, or 5.6% of total data center revenues.

Management expects to ship nearly four times the quantity of 800G units in the second quarter as additional orders move into delivery. The company also announced a first volume order for 1.6T transceivers from another long-term hyperscale customer, with 800G deliveries expected in the second quarter and 1.6T deliveries expected as early as the third quarter, completing by year-end 2026.

AAOI’s ability to scale manufacturing capacity rapidly remains a key catalyst. The company has made significant investments in expanding its U.S. manufacturing footprint, especially in Texas, and internationally in Taiwan and China.

The company expects to produce more than 650,000 units of 800G and 1.6T products per month by the end of 2026, and anticipates increasing this to more than 930,000 units per month by the end of 2027. This expansion is crucial, as demand for these high-speed modules is projected to outpace production capacity through mid-2027, underscoring the strength and persistence of the AI infrastructure trend.

AAOI’s strong position in the 800G transceiver market is fueling both operational and financial momentum. The company forecasts that 800G revenues will reach approximately $217 million per month by mid-2027, contributing to a total data center transceiver revenue of about $471 million monthly.

AAOI Faces Stiff CompetitionApplied Optoelectronics is facing stiff competition from Lumentum (LITE - Free Report) and Coherent (COHR - Free Report) in the optical networking market. Coherent and Lumentum’s partnerships with NVIDIA pose a significant threat to AAOI.

During the third quarter of fiscal 2026, Coherent announced a strategic partnership with NVIDIA focused on advanced optical networking and CPO technologies for AI data centers. The agreement includes a $2 billion equity investment from NVIDIA and a multi-year supply agreement extending through the end of the decade.

In March 2026, Lumentum entered into a multiyear strategic agreement with NVIDIA to accelerate the development of advanced optical technologies for next-generation AI infrastructure. The partnership includes a multibillion-dollar purchase commitment and a $2 billion NVIDIA investment to expand Lumentum’s U.S. manufacturing capacity and R&D capabilities.

AAOI’s Share Price Performance, Valuation, and EstimatesApplied Optoelectronics shares have skyrocketed 250.6% in the year-to-date period, outperforming the Zacks Computer & Technology sector’s rise of 15.3% and the Zacks Electronics - Semiconductors increase of 44.9%.

AAOI Stock’s Performance
Image Source: Zacks Investment Research

Applied Optoelectronics shares are currently overvalued, as suggested by its Value Score of F. AAOI stock is trading at a premium with a trailing 12-month Price/Sales of 18.32X compared with the Electronics - Semiconductors industry’s 16.35X.

AAOI’s Valuation
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for 2026 earnings is pegged at 80 cents per share, which has been unchanged over the past 30 days. This suggests 407.69% year-over-year growth.

AAOI’s Zacks RankApplied Optoelectronics currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. 

Key Takeaways D-Wave was named a Leader in the IDC MarketScape Worldwide Quantum Computing 2026 Vendor Assessment.QBTS reported 200M submitted problems, with Advantage2 usage up 314% year over year.D-Wave's roadmap targets 10 logical qubits by 2030 and 100 logical qubits by 2032. D-Wave Quantum (QBTS - Free Report) , or D-Wave, has been recognized as a Leader in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. The evaluation assessed vendors based on both their existing capabilities and future strategies. According to the company, the recognition comes as organizations increasingly seek practical quantum solutions that can be integrated into existing enterprise and high-performance computing environments.

The report highlighted several of D-Wave’s strengths, such as its broad production deployment footprint, spanning operational manufacturing, telecommunications, retail, logistics, defense, and research computing workflows. D-Wave submitted more than 200 million problems to its systems. The usage of its Advantage2 system grew 314% year over year, while the Stride hybrid solver usage expanded 114% over the six months as of early 2026.

IDC also highlighted that the company’s enterprise accessibility and hybrid adoption framework, including the Leap cloud platform, Ocean SDK, the Stride hybrid solver and the Leap Quantum LaunchPad onboarding program. These tools help organizations to apply quantum-assisted optimization to problems involving up to 2 million variables without requiring dedicated quantum programming expertise. Beyond optimization, IDC recognized D-Wave’s active effort to extend quantum annealing into scientific computing domains relevant to materials science, electronics, medical imaging, and physical systems modeling.

Another highlight was D-Wave’s roadmap, which includes both continued scaling of quantum annealing systems and expansion into gate-model quantum computing. Key roadmap milestones for the gate-model program include the completion of a 10-logical-qubit system by 2030, which can support the first fault-tolerant algorithms, and completion of a 100-logical-qubit system by 2032, which can support initial quantum chemistry and quantum AI applications.

IDC noted that D-Wave’s dual-platform strategy broadens its long-term opportunity to address a wider range of enterprise workloads as the market evolves.

Key Developments Among QBTS PeersQualcomm Inc. (QCOM - Free Report) recently announced a strategic multi-generation collaboration with Meta to be a supplier for data center CPUs for the latter. Qualcomm Technologies’ data center CPU, the Qualcomm DragonflyC1000, is planned to power Meta’s next-generation server fleet, highlighting the growing importance of high-performance, power-efficient compute in large-scale, scale-out environments. The company’s solutions will be in production starting in the second half of 2028 for future data center capacity expansions.

Intel (INTC - Free Report) has unveiled innovations at Computex 2026 that address customers’ chip-to-systems-level AI needs with solutions tailored to address their specific industry challenges. The company announced rackscale AI infrastructure for customers interested in scaling their inference and agentic workloads based on Intel Xeon processors and SambaNova SN-50 Reconfigurable Dataflow Units. Intel also announced strategic collaborations with Foxconn, Siemens, Hitachi, Echo Neurotechnologies and Greenstone Biosciences to deliver integrated vertical customer solutions based on Intel processors and purpose-built silicon.

The Zacks Rundown for QBTS StockOver the past 12 months, QBTS shares have risen 32.1% against the industry’s 15.6% decline. 

Image Source: Zacks Investment Research

D-Wave is trading at a forward, one-year Price/Sales (P/S) of 116.55X, lower than its 169.78X median but significantly above the industry average of 3.89X.

Image Source: Zacks Investment Research

Take a look at how estimates for D-Wave’s 2026 and 2027 earnings are shaping up.

Image Source: Zacks Investment Research

D-Wave currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Michael N. Intrator, CEO and President of CoreWeave, Inc. (CRWV 0.04%), reported a sale of 369,489 shares of Class A Common Stock on July 7, 2026 and July 8, 2026, according to a recent SEC Form 4 filing.

Transaction summaryMetricValueShares sold (total)369,489Shares sold (directly held)261,797Shares sold (indirectly held)107,692Transaction value$30.8 millionPost-transaction shares (directly held)2,876,815Post-transaction value$258.9 millionTransaction value based on SEC Form 4 weighted average sale price ($83.37); post-transaction value based on July 08, 2026 market close ($90.00).

Key questionsWhat was the structural nature of this transaction?
Part of the transaction was a conversion-for-sale event involving the conversion of 107,692 Class B shares into Class A. The remainder were from directly-held stock.What is the insider's remaining equity footprint?
Following this sale, Intrator maintains significant exposure to the company through 2,876,815 shares held directly. Furthermore, the insider retains substantial derivative holdings, including ~21.9 million derivative securities held directly and ~30.7 million held indirectly through various family trusts.Which indirect entities were involved in the disposition?
The indirect portion of the sale, totaling 107,692 shares, was executed by Omnadora Capital LLC. While this liquidated the direct Class A position for that entity, other family-related entities, including the PMI 2024 F&F GRAT and the Intrator Family Trust, continue to hold significant derivative positions.How does this sale align with recent stock performance?
The shares were sold at a weighted average price of $83.37 as the company faced a one-year return of -41% as of the July 7, 2026 transaction date. Despite the recent price performance, the insider's remaining beneficial ownership represents approximately 0.53% of the company's $49.1 billion market capitalization.Company OverviewMetricValueShare Price (as of market close 2026-07-08)$90.00Market Capitalization$49.1 billionRevenue (TTM)$6.2 billionNet Income (TTM)-$1.6 billionCompany SnapshotCoreWeave operates a specialized cloud computing platform that delivers high-performance GPU and CPU compute resources, storage solutions, advanced networking capabilities, and fully managed services designed to support generative AI and intensive compute workloads for enterprise clients.The company generates revenue through a flexible consumption-based model, offering customers the choice between virtual server instances and bare-metal infrastructure solutions tailored to their specific computational requirements.CoreWeave primarily serves large enterprises and organizations requiring substantial computational resources for generative AI applications, machine learning workloads, and data-intensive processing operations.CoreWeave operates as a specialized infrastructure provider in the rapidly expanding generative AI compute market, with a market capitalization of $49.1 billion and TTM revenues of $6.2 billion. The company differentiates itself through purpose-built infrastructure optimized for AI workloads, providing enterprises with flexible, scalable alternatives to traditional cloud providers.

As a growth-stage infrastructure company, CoreWeave is positioned to capture significant market share in the emerging AI compute infrastructure segment, though the company is currently operating at a net loss as it invests in capacity expansion and market penetration.

What this transaction means for investorsCoreWeave CEO Michael Intrator’s July 7 and July 8 sale of company stock came at a time when shares were well below the 52-week high of $153.20 reached in 2025. While involving almost 370,000 shares, the disposition does not appear to be a red flag for investors.

Intrator’s sale represented only a small portion of the millions of shares he maintained post-transaction. In addition, the sale was executed as part of a pre-established Rule 10b5-1 plan, making this a non-discretionary transaction. Such plans allow insiders to sell shares at predetermined times to avoid concerns of trading on non-public information.

CoreWeave is seeing strong sales growth thanks to the artificial intelligence boom. In the first quarter, it generated $2.1 billion in revenue compared to $982 million in 2025. The stock is down, however, because the company is not profitable and is burdened with over $25 billion in debt as it seeks to expand its footprint of data centers to house AI systems.

Robert Izquierdo has positions in CoreWeave. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

SpaceX SPCX shares fell more than 2% on Friday, extending a volatile stretch that has erased the stock's post-IPO gains as investors continue debating whether Elon Musk's AI and space ambitions justify one of the world's richest valuations.

The stock traded around $148, below its $150 listing price, after briefly soaring to a record closing high of $201.80 on June 16 following its blockbuster market debut.

The sharp swings come as Wall Street publishes its first wave of research following SpaceX's record-setting IPO, with analysts offering differing views on the company's long-term potential.

Veteran investor Jeremy Grantham was among the most outspoken critics, describing the IPO as a potential landmark market bubble in a recent interview with Morningstar.

Grantham argued that much of SpaceX's valuation rests on aggressive assumptions about artificial intelligence despite what he described as the company's relatively weak competitive position in AI software.

He also questioned projections around orbital AI infrastructure and broader space-related opportunities outlined in the IPO prospectus, arguing they require technological advances that remain highly speculative.

Grantham said the stock could continue rising in the near term because of strong investor demand and index-related buying, but maintained that the valuation would ultimately have to be supported by fundamentals.

Musk remains bullishMusk, however, has continued to raise expectations.

Responding to comments on X this week, the SpaceX chief executive said the company could eventually become "worth more than the rest of Earth" if it achieves its long-term goals.

The remarks add to a series of ambitious projections from Musk, who has previously argued Tesla could become more valuable than Apple and Saudi Aramco combined.

Several Wall Street firms have also outlined aggressive long-term scenarios for SpaceX, driven largely by expectations for Starlink, reusable launch systems, and future AI infrastructure businesses.

Raymond James currently has one of the Street's highest published price targets at $800 per share, while Citi's bull-case scenario values the company at roughly $12 trillion.

SpaceX also faces growing competition overseas.

China on Friday successfully landed the booster stage of its reusable Long March-10B rocket, marking the country's first successful recovery of an orbital-class reusable booster.

The milestone places China's Aerospace Science and Technology Corp. alongside SpaceX and Blue Origin among the small group of organizations to demonstrate reusable rocket landing capability.

While SpaceX remains the clear global leader in reusable launch technology, China's latest achievement highlights the increasing pace of competition in the commercial space industry as governments and private companies race to lower launch costs and expand access to orbit.

SpaceX's pullback follows an explosive start to life as a public company, with the stock surging more than 30% in its first few trading sessions before reversing sharply.

The combination of lofty valuation expectations, ambitious long-term projections, and limited public trading history has left the shares particularly sensitive to shifts in investor sentiment.

With Wall Street still establishing coverage and investors trying to assess the company's AI, satellite, and launch businesses under one public valuation, analysts expect trading to remain volatile in the months ahead.

Optimism says Toss is the fourth regulated financial institution in a year to pick the OP Stack, after Bitpanda, Kraken and Mitsui.

Toss, the South Korean fintech app with roughly 30 million registered users, is testing a Korean won stablecoin on Optimism's OP Stack, Optimism said on X Wednesday. The proof of concept also involves Sunnyside Labs, whose "Privacy Boost" tool is meant to shield transaction data on a public blockchain while preserving compliance access.

Optimism, the company behind the OP Stack framework used to build layer-2 networks, called the tie-up the fourth time in a year a regulated financial institution has adopted the OP Stack in a new market, following Bitpanda's Vision Chain in Europe, Kraken's Ink in the US and Mitsui's Zipangcoin in Japan.

Kyle Jenke, chief business officer at OP Labs, said the pilot is "about demonstrating that the OP Stack can meet the compliance, privacy, and performance standards that regulated financial institutions require." Toss chief business officer Q-Ha Steve Kim said the company aims "to build a highly trusted, compliant digital financial infrastructure tailored to the Korean market," using the same post.

Three-Month TestThe arrangement runs as a three-month proof of concept, according to a post from crypto researcher Jay Chan, covering whether a financial institution can manage settlement, meet KYC and anti-money-laundering requirements, and protect transaction privacy on a public chain at the same time. Toss operates over 500,000 online and offline payment networks, per a summary of Kim's comments on the deal.

Optimism's post frames the collaboration as a test rather than a commitment to launch a stablecoin.

The OP Stack already underpins Sony's Soneium, Uniswap's Unichain and OKX's X Layer, among others, giving Toss an established multi-chain ecosystem to plug into rather than building isolated infrastructure. Whether the pilot converts into a live KRW stablecoin will depend on regulatory sign-off in South Korea, which has not yet finalized its stablecoin licensing framework.

Key Takeaways UnitedHealth launched a Lifestyle Spending Account integrated with the UHC Store for eligible members.UNH's LSA supports fitness, nutrition, sleep and more without reimbursement claims.UnitedHealth says the benefit complements broader digital health and member experience initiatives. UnitedHealth Group Incorporated (UNH - Free Report) , through UnitedHealthcare, has launched a Lifestyle Spending Account (“LSA”), expanding its portfolio of consumer-focused health benefits. The employer-sponsored, post-tax account is integrated with UHC Store, enabling eligible members to shop for approved health, wellness and lifestyle products without submitting reimbursement claims. By integrating the benefit directly into its digital platform, UNH is simplifying the purchasing process while giving employers a flexible way to support employees' evolving wellness needs.

The launch reflects a broader shift toward personalized workplace benefits. Unlike traditional health accounts that cover only qualified medical expenses, the LSA extends support to categories such as fitness, nutrition, sleep, mindfulness, women's health and weight management. The platform is available to more than 15 million UnitedHealthcare commercial members and features over 30 offerings from dozens of vendors.

For UNH, the initiative strengthens its strategy of building a more connected digital healthcare ecosystem. Integrating the LSA with UHC Store simplifies administration for employers by reducing reimbursement hassles and limiting the need for relationships with multiple vendors. It also complements the company's recent efforts to improve the member experience, including easing prior authorization requirements, expanding maternity support, enhancing cancer screening coverage and introducing its AI assistant, Avery.

However, the LSA is unlikely to materially boost near-term earnings but strengthens UNH's long-term value proposition. Greater consumer choice, stronger digital engagement and flexible employer solutions can improve member satisfaction and client retention. As workplace healthcare continues to evolve, such initiatives could help UNH deepen employer relationships and reinforce its competitive position in commercial health benefits.

How Are Competitors Faring?Some of UNH’s major competitors in the medical space are Humana Inc. (HUM - Free Report) and Elevance Health, Inc. (ELV - Free Report) .

Humana is strengthening its employer-sponsored health benefits portfolio through expanded virtual care, wellness and preventive health programs. HUM emphasizes integrated care models that improve member engagement, promote healthier lifestyles and help employers enhance workforce health while managing costs.

Elevance Health is expanding its employer-sponsored health benefits capabilities through the Carelon platform, which integrates pharmacy, behavioral health and care management with digital solutions. ELV continues to invest in personalized care offerings that improve employee health outcomes while helping employers better manage healthcare spending.

UnitedHealth’s Price Performance, Valuation & EstimatesShares of UNH have gained 42% in the past year compared with the industry’s growth of 35.1%.

Image Source: Zacks Investment Research

From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 22.01, above the industry average of 18.50. UNH carries a Value Score of B.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for UnitedHealth’s 2026 earnings is pegged at $18.32 per share, implying 12.1% growth from the year-ago period.

Image Source: Zacks Investment Research

UNH stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways Block's consumer-lending originations rose 82% year over year to $17.6 billion in first-quarter 2026.XYZ expanded Cash App Borrow and Afterpay offerings, lifting Financial Solutions gross profit 55%.Block's lending growth came with higher credit losses, though cash and operating cash flow remain strong. Block Inc.’s (XYZ - Free Report) consumer-lending business is emerging as a key growth driver, fueled by the rapid adoption of Cash App Borrow and Afterpay. Consumer-lending originations reached $17.6 billion in the first quarter of 2026, up 82% year over year, led by a roughly 175% increase in Cash App Borrow originations as eligibility expanded to more Cash App Green customers.

Block continues to broaden its lending ecosystem through Afterpay's installment offerings, including Post-Purchase, Pre-Purchase, Pay Monthly and BNPL options integrated into Cash App Pay and peer-to-peer payments. The strategy is driving higher engagement and monetization. Financial Solutions gross profit climbed 55% year over year in the first quarter, while Cash App Financial Solutions gross profit per active customer increased 60%. Overall, Cash App gross profit rose 38%, with lending among the largest contributors.

Rapid expansion, however, has been accompanied by higher credit costs. Transaction, loan and consumer receivable losses rose to $500 million in the first quarter from $170 million a year earlier. The allowance for credit losses on loans held for investment increased 26% sequentially to $482.8 million, while classified higher-risk loans grew 23% to $467.3 million.

Cash App Borrow gross loss rates ranged from 3.16% for newer borrowers to 2.67% for customers with more than 13 months of tenure, indicating relatively stable cohort performance. With $6.86 billion in cash and strong operating cash flow, Block appears well positioned to support lending growth, provided gross profit continues to outpace normalized credit losses.

How Are Block’s Competitors Faring?Dave Inc.’s (DAVE - Free Report) offers ExtraCash advances of up to $500 with no interest, credit checks or late fees. In first quarter 2026, DAVE reported $158.4 million in revenue, up 47%, while ExtraCash originations rose 37% to $2.1 billion. DAVE also reached roughly 3 million monthly transacting members.

SoFi Technologies (SOFI - Free Report) competes through larger unsecured personal loans for debt consolidation and major expenses. SOFI originated $8.3 billion in personal loans in the first quarter 2026. Unlike short-term cash advances, SOFI uses fixed monthly installments and serves borrowers seeking larger loan amounts.

XYZ’s Price Performance, Valuation & EstimatesShares of Block have rallied 20.5% over the past three months, outperforming the broader industry and the S&P 500 Index.

Image Source: Zacks Investment Research

In terms of forward 12-month P/E, XYZ stock is trading at 17.30X, which is at a discount to the Zacks Internet Software industry’s 27.09X.

Image Source: Zacks Investment Research

Block’s earnings estimate revisions reflect a positive trend. The Zacks Consensus Estimate for full-year 2026 EPS has been revised marginally northward. The figure indicates a significant increase year over year.

Image Source: Zacks Investment Research

Block currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Throughout the massive growth of artificial intelligence and the infrastructure that powers it, Taiwan Semiconductor Manufacturing (TSM 0.04%) has been a consistent winner. TSMC, as it’s known, is the world’s largest chip foundry, producing advanced semiconductors for Nvidia, Advanced Micro Devices, Broadcom, and many others.

TSMC holds a dominant 73% market share in the global foundry market, with second-place Samsung at only 7%. But a Japanese company, Rapidus, is taking aim at TSMC, with plans to mass-produce advanced 2 nm chips while undercutting TSMC on price.

TSMC started producing 2 nm chips this year, and they’re reportedly priced at $30,000 per wafer. Rapidus, which is reportedly in talks with more than 60 companies, would reportedly price its 2 nm process at about $21,000 per wafer, but the company doesn’t plan to enter production until 2027.

Can Rapidus really pose a threat to TSMC’s dominance? I don’t think so, and here’s why.

Image source: The Motley Fool.

TSMC's track record can’t be touchedIt’s hard to overstate the impact that TSMC has had on the industry. Nvidia CEO Jensen Huang has repeatedly praised the company -- in a 2025 news conference, he was nearly gushing: "They are a world-class foundry and support customers of diverse needs. You can't overstate the magic that is TSMC," he said. And during a visit to Taiwan, he called TSMC “one of the greatest companies in the history of humanity.”

One reason for TSMC’s dominance is its open innovation platform, which the company uses to collaborate with customers in their chip designs. TSMC says that through its platform, the company has been involved with 85% of global start-up semiconductor prototypes. In all, TSMC produced more than 12,600 different products in 2025 using 305 separate process technologies.

TSMC also excels at making chips with more advanced process nodes, meaning that designers can pack more of them on individual chips to make them more powerful. In the first quarter, 25% of TSMC’s revenue came from building 3 nm chips and 36% came from building 5 nm chips. That’s a big change from 2023, when only 6% of TSMC’s revenue came from 3 nm chips and 33% came from 5 nm chips. It hasn’t yet reported 2 nm sales, but those will likely be discussed when TSMC files its second-quarter earnings on July 16.

TSMC’s revenue in the first quarter was $35.9 billion, up 40.6% from a year ago. And it forecasts revenue between $39 billion and $40.2 billion, with an operating profit margin between 56.5% and 58.5%.

The challenges facing RapidusLaunched in 2022 with the backing of the Japanese government, Rapidus will be hard-pressed to break through TSMC’s dominance. Not even established chipmakers like Samsung or Intel have been able to gain meaningful market share.

Today's Change

(

-0.04

%) $

-0.16

Current Price

$

436.80

Rapidus has only a pilot line in operation and plans to open a second fab next year as it ramps up. But it still needs to prove it can manufacture at scale while making a reasonable profit. Management already seems to be hedging on the possible price, stating in a news release that “semiconductor prices vary significantly depending on the specifications of the products ordered by semiconductor design companies and are subject to fluctuations due to factors such as exchange rates.”

So, even if Rapidus can match or just slightly undercut TSMC prices, would major companies have an incentive to switch suppliers? It’s unlikely.

Top semiconductor companies don’t choose their manufacturing partners based on price alone. TSMC has proven itself a reliable partner that delivers high-quality work at scale -- work that has helped Nvidia, Broadcom, AMD, and other chip companies soar to new heights. TSMC will have more than a year of mass-producing 2 nm chips before Rapidus can even get started.

Even with the backing of the Japanese government, it’s highly unlikely that Rapidus will pose a threat to TSMC, and investors shouldn’t be concerned about its undercutting strategy.

Key Takeaways TXN's Embedded processing revenues rose 12% to $723 million in Q1'26, while profit more than tripled.Texas Instruments benefits from rising chip use in factories, vehicles, medical devices and networks.TXN's Internal 300-mm wafer production lowers costs and improves supply reliability as demand recovers. Texas Instruments Incorporated’s (TXN - Free Report) embedded processing business has returned to healthy growth, raising hopes that the segment can remain an important driver of the company’s long-term performance. Although the analog business remains the largest contributor, embedded processing is benefiting from improving industrial demand and increasing semiconductor content across connected devices, vehicles and factory automation.

In the first quarter of 2026, embedded processing revenues increased 12% year over year to $723 million. The segment’s operating profit more than tripled to $122 million from $40 million a year earlier, reflecting stronger sales and better factory utilization. The recovery shows that customer inventory adjustments are easing and end-market demand is gradually improving.

Texas Instruments is well-positioned to benefit from long-term growth trends. Its portfolio of microcontrollers and processors is widely used in industrial equipment, automotive systems, medical devices and communications infrastructure. Growing adoption of smart factories, advanced driver-assistance systems and connected industrial equipment is expected to increase demand for embedded chips over the coming years.

The company also benefits from its manufacturing strategy. Greater use of internally produced 300-millimeter wafers helps lower production costs while improving supply reliability. This gives Texas Instruments an advantage in serving customers during periods of rising demand.

However, management remains cautious about the second half of 2026 due to macroeconomic uncertainty and uneven demand across some markets. Automotive demand also remains mixed in certain regions. Even so, improving industrial activity, growing automation investments and expanding applications for embedded processors provide a favorable backdrop.

If these trends continue, Texas Instruments’ embedded business appears well-positioned to extend its double-digit growth run and contribute meaningfully to overall revenue and profit growth. The Zacks Consensus Estimate for TXN’s 2026 embedded processing revenues is currently pegged at $3 billion, indicating 11.4% year-over-year growth.

How Rivals Fare Against TXN in the Embedded Chip MarketMicrochip Technology Incorporated (MCHP - Free Report) and NXP Semiconductors N.V. (NXPI - Free Report) are two leading competitors of Texas Instruments in the embedded processing market.

Microchip Technology offers a broad portfolio of microcontrollers, microprocessors and connectivity solutions used in industrial automation, automotive electronics and aerospace applications. The company is benefiting from broad-based demand improvement across end markets, stronger customer engagement and normalization of inventory levels across its supply and distribution channels. In the last reported financial results for the fourth quarter of fiscal 2026, Microchip Technology’s revenues surged 35% year over year to $1.31 billion.

NXP Semiconductors is another strong rival, with a leading position in automotive processors, secure connectivity and industrial embedded systems. Automotive accounts for more than half of NXPI’s revenue, supported by growing semiconductor content in electric vehicles and advanced driver-assistance systems. NXP Semiconductors is also expanding its edge AI and industrial IoT offerings to capture long-term growth opportunities. However, softer vehicle production in Europe and China has weighed on near-term sales. In the first quarter of 2026, NXP Semiconductors’ revenues increased 12% year over year to $3.18 billion.

TXN’s Price Performance, Valuation and EstimatesShares of Texas Instruments have soared 77.8% year to date compared with the Zacks Semiconductor - General industry’s 19.3% growth.

Texas Instruments YTD Price Return Performance
Image Source: Zacks Investment Research

From a valuation standpoint, TXN trades at a forward price-to-earnings ratio of 37.43, significantly higher than the industry’s average of 22.65.

Texas Instruments Forward 12-Month P/S Ratio
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Texas Instruments’ 2026 and 2027 earnings implies a year-over-year increase of 40.6% and 14.4%, respectively. Estimates for 2026 have remained unchanged over the past 60 days, while estimates for 2027 have been revised upward during the same time frame.

Image Source: Zacks Investment Research

Texas Instruments currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© krystiannawrocki / E+ via Getty Images

I keep hitting the buy button on Broadcom (NASDAQ:AVGO | AVGO Price Prediction), and every quarter Hock Tan gives me a fresh reason to do it again. I own the boring chipmaker, keep adding on weakness, and the last four quarters keep telling me I am not early enough.

The thesis: every AI cluster needs custom accelerators and Ethernet fabric before GPUs can talk to each other. Broadcom sells that wiring under multi-year commitments that turn a volatile silicon cycle into something closer to a toll road.

The Data Doing the Arguing AI semiconductor revenue hit $10.80 billion in Q2 FY2026, up 143% year over year, and Tan guided Q3 to $16 billion, up over 200% year on year. He put full-year 2026 AI revenue at $56 billion and fiscal 2027 at in excess of $100 billion. Q2 AI bookings landed at over $30 billion against $10.8 billion shipped, which is why he said visibility “extends into 2028.”

Q2 free cash flow was $10.26 billion, or 46% of revenue. Adjusted EBITDA margin ran at 69%. Operating income rose 85.07% year over year on 48% revenue growth. Cash on the balance sheet climbed to $19.63 billion, up 107.22% year over year, while total liabilities fell 3.76%.

The dividend was raised 10% in Q4 FY2025 to $0.65 per share, marking 15 consecutive annual increases since fiscal 2011. A fresh $10 billion buyback was authorized in March 2026, and management already put $7.8 billion of that to work in Q1. Eight straight EPS beats round it out.

SoFi Active Invest is offering a limited-time promotion. Open an account, fund it with $50 or more, and you could receive up to $1,000 in complimentary stock for Active Invest accounts. See for yourself by clicking here now.

Why Not the Obvious Names Why not just pile into NVIDIA (NASDAQ:NVDA) or Advanced Micro Devices (NASDAQ:AMD) or Marvell Technology (NASDAQ:MRVL)? First, none pair AI exposure with a 15-year rising dividend the way Broadcom does, and my retirement account needs the income compounding. Second, Broadcom is the counterparty for custom silicon hyperscalers build instead of buying merchant GPUs, with named commitments from Google, Meta, OpenAI, and Anthropic, including a 1.3-gigawatt OpenAI deployment in 2027 and a 3-gigawatt Meta program through end of 2028. Own the toll booth, and you are indifferent to which car wins the race.

The Risk I Am Not Dismissing Concentration is real. A handful of hyperscalers drive the AI number, and the filing flags “dependence on limited number of significant customers” as a risk. What keeps me buying is the backlog shape: $30 billion of Q2 bookings and gigawatt commitments stretching into 2028 look less like a single-quarter demand pulse and more like a build-out schedule.

Insiders have been net sellers over the past 90 days. Retail chatter on the Apple extension stayed muted while the stock rose 11.28% in a week and 45.4% over the past year. Analyst consensus target sits at $523.73, with 44 buy or strong buy ratings and zero sells. I will keep buying Broadcom until Hock Tan stops raising the AI number.

Want Up To $1,000? SoFi Is Giving New Active Invest Users Free StockLooking to grow your money but unsure where to begin? SoFi Active Invest is offering a limited-time promotion—open an account, fund it with $50 or more, and you could receive up to $1,000 in complimentary stock for Active Invest accounts.

From $0 commission trading to fractional shares and automated investing, this app is designed to simplify investing for everyone, whether you’re just starting or already experienced. Its easy to sign up and secure your bonus. 

Contact [email protected] for any questions or corrections.

Spotify Technology SA (NYSE:SPOT) is expected to post accelerating revenue growth in the second quarter, according to UBS, with results likely to come in largely in line with management's outlook on the back of price increases and stable gross margins.

The bank forecasts second-quarter revenue of €4.8 billion, up 15.6% on a foreign exchange neutral basis, compared with 14.2% growth in the first quarter.

UBS expects 6 million premium net additions, down from 8 million a year earlier, citing longer conversion times tied to new free tier features, a shift in campaign marketing timing and a tougher iOS comparison.

Premium average revenue per user is expected to grow 8.1% year over year on an FXN basis, while advertising revenue growth is expected to improve as the company laps lower podcast inventory from last year, with further acceleration anticipated in the second half as self-serve and programmatic channels expand.

UBS forecasts gross margins expanding 160 basis points year over year to 33.1%, and operating income of €634 million for the quarter.

Looking further out, UBS is largely maintaining its 2026 estimates, projecting €19.4 billion in annual revenue, up 14.3% FXN, and gross margins of 33.3%. The bank expects free cash flow of €3.4 billion in 2026, up 18% year over year, and anticipates Spotify will ramp up share buybacks following the cash repayment of its convertible notes in March.

UBS rates Spotify shares Buy and lowered its price target to $690 from $735, reflecting slightly lower EBITDA estimates on higher opex and a reduced forward multiple. The bank pointed to new AI tools and premium tier offerings as potential drivers of deeper user engagement and improved premium conversion over the medium to long term.

Key Takeaways ELV is balancing shareholder returns with investments in Carelon and AI to support long-term growth.ELV generated $4.3B operating cash flow and returned about $1.5B via dividends and share repurchases.ELV's ROIC of 8.3% tops the industry average, while a $5.6B buyback authorization remains available. Elevance Health, Inc. (ELV - Free Report) is using a disciplined capital allocation strategy to balance shareholder returns with long-term business expansion. The company continues to invest in growth initiatives while returning excess cash through dividends and share repurchases. This balanced approach supports financial flexibility and positions ELV to navigate an evolving healthcare landscape without sacrificing future earnings potential.

The company's capital allocation is supported by robust cash generation. In the first quarter of 2026, ELV generated $4.3 billion in operating cash flow, up sharply from $1 billion a year ago, and expects full-year operating cash flow to be at least $5.5 billion. During the quarter, it returned around $1.5 billion to shareholders through $376 million in dividends and $1.1 billion in share repurchases. With $5.6 billion remaining under its share repurchase authorization as of March 31, 2026, the company retains significant flexibility to continue rewarding shareholders.

Additionally, ELV is directing capital toward businesses with attractive long-term growth prospects. The company continues to expand Carelon's capabilities across pharmacy, behavioral health, home-based care and value-based care while scaling AI to improve member engagement, reduce administrative costs and strengthen care management. These investments are expected to improve operating efficiency and diversify earnings beyond the traditional health insurance business.

Strong cash generation gives ELV the flexibility to fund growth initiatives while maintaining shareholder returns. Its ROIC of 8.3% exceeds the industry average of 6.6%. If the company continues executing this balanced strategy, its disciplined use of capital could support sustainable earnings growth and create lasting shareholder value.

How Are Competitors Faring?Some of ELV’s competitors in the medical space are UnitedHealth Group Incorporated (UNH - Free Report) and Humana Inc. (HUM - Free Report) .

UnitedHealth generates solid cash from operations and returns value to investors via share repurchases and dividend payouts. In the first quarter of 2026, cash flows from operations were $8.9 billion, up 63.3% year over year. During the quarter, UNH paid dividends worth $2 billion.

Humana's strong financial position, supported by solid cash reserves and robust cash flows, has enabled it to return capital to shareholders. HUM generated net cash from operations of $1.3 billion in the first quarter of 2026, up nearly fourfold year over year. It repurchased shares worth $107 million in the first quarter of 2026 and paid dividends of $107 million.

Elevance Health’s Price Performance, Valuation & EstimatesShares of ELV have risen 19.9% in the year-to-date period against the industry’s fall of 0.1%.

Image Source: Zacks Investment Research

From a valuation standpoint, Elevance Health trades at a forward price-to-earnings ratio of 15, below the industry average of 16.38. ELV carries a Value Score of A.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Elevance Health’s 2026 earnings is pegged at $26.86 per share, implying an 11.3% drop from the year-ago period.

Image Source: Zacks Investment Research

ELV stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

AppLovin Corp (NASDAQ:APP) is gaining share of e-commerce advertising budgets as brands increase spending on the platform, according to a Jefferies survey of advertisers using the company’s advertising technology in the second quarter of 2026.

Jefferies surveyed 30 e-commerce and web advertisers using AppLovin in 2Q26 and found that AppLovin’s share of advertiser budgets increased by 169 basis points compared with the fourth quarter of 2025, reaching 11.1% of spend in 2026.

The firm noted that AppLovin maintained its position among the top three advertising networks by both budget share and return on ad spend (ROAS), ranking just ahead of TikTok.

The survey found that TikTok also gained share during the period, while Meta and Google accounted for most of the budget share losses. Jefferies wrote that the shift was primarily driven by advertisers diversifying incremental ad spend toward platforms including AppLovin and TikTok rather than reducing spending on Meta and Google.

The survey captured a greater proportion of advertisers that had joined AppLovin in the fourth quarter of 2025, with those advertisers representing 23% of respondents compared with 7% in Jefferies’ previous survey. The firm noted that these newer advertisers have continued to scale spending throughout 2026.

Jefferies also highlighted improving feedback on AppLovin’s generative artificial intelligence tools. Half of surveyed advertisers had tested AI-generated end cards, half had tested AI-generated video, and one-third had tested full campaign setup using generative AI features.

The firm wrote that feedback on AI-generated video was particularly positive, with six advertisers reporting ROAS improvements. Advertisers cited the ease of use and ability to test multiple videos as benefits. Jefferies noted that prior feedback on AppLovin’s AI video product had been more muted, making the latest results an incremental positive.

Feedback on AI-generated end cards was mixed, with advertisers describing the tool as intuitive and easy to use, though only four respondents reported performance improvements. For full campaign setup, advertisers focused more on improved speed and campaign launch efficiency rather than direct performance gains, according to Jefferies.

Advertisers surveyed also raised their expectations for direct-to-consumer ad spending growth in 2026. Respondents now expect total DTC ad spend to increase 15% year-over-year, up from an 8% growth expectation in Jefferies’ first-quarter survey. The group reported 12% spending growth in the second quarter and expects a similar pace in the third quarter.

AppLovin’s prospecting and discovery campaigns also showed improvement in the survey. Jefferies found that 73% of respondents reported an increase in new customer revenue from prospecting campaigns, up from 60% in the prior survey, while the percentage seeing a significant increase rose to 30% from 13%. For discovery campaigns, 60% of advertisers reported increased benefits, compared with 50% previously.

Jefferies’ survey cohort represented more than $1.2 billion in direct-to-consumer advertising spend and at least $7.1 billion in gross merchandise value, based on the firm’s estimates.

Shares of AppLovin traded hands at $514 on Friday, down almost 24% so far this year.

Key Takeaways Allegro's thesis ties EVs, ADAS, AI data centers and robotics to broader semiconductor demand.Automotive generated $628.6 million, or 70.6% of fiscal 2026 revenue, keeping vehicle demand central.Fiscal 2026 revenue rose 22.8% to $890.1 million as non-GAAP EPS more than doubled to 54 cents. Allegro MicroSystems, Inc. (ALGM - Free Report) has moved beyond a narrow automotive chip story. Its investment case now rests on whether rising semiconductor content in electric vehicles, advanced driver assistance systems, artificial intelligence data centers and robotics can translate into steadier growth.

That shift matters because the stock no longer depends only on vehicle production. Investors are also watching margins, operating leverage and whether newer markets can reduce auto cyclicality over time.

How Allegro Taps Four Growth MarketsAllegro’s growth thesis centers on systems that need more sensing, motor control and power management. Its magnetic sensors provide current, position, angle and speed feedback, while motor drivers, isolated gate drivers and power integrated circuits support motion control and power conversion.

Those products map directly to electric vehicles, advanced driver assistance systems, AI infrastructure and robotics. Texas Instruments (TXN - Free Report) is relevant in the same broader analog and power-management landscape, while Infineon Technologies AG (IFNNY - Free Report) also targets automotive systems such as electric drivetrains, braking and steer-by-wire.

ALGM Still Runs Through AutomotiveAutomotive remains Allegro’s base business. In fiscal 2026, automotive revenues were $628.6 million, or about 70.6% of total revenues, showing that the company’s broader story still runs through vehicle demand.

That is a strength because Allegro has deep automotive relationships and products aligned with electric powertrains and advanced safety systems. It is also a concentration risk, since downturns or disruptions in the auto market remain an explicit business risk.

Allegro Finds New Fuel in Data CentersThe newer upside is coming from industrial and other markets, especially AI data centers. In the fourth quarter of fiscal 2026, data centers reached a record 14% of sales, rising 41% sequentially, while industrial and other sales increased 49% year over year.

These applications matter because Allegro’s motor drivers support data center cooling, while current sensors and isolated gate drivers address power efficiency and density. If adoption continues, non-automotive markets could diversify revenue and support a higher growth profile.

ALGM Profit Recovery Is Gaining TractionFiscal 2026 showed a clear financial recovery. Revenues rose 22.8% year over year to $890.1 million, and non-GAAP earnings per share more than doubled to 54 cents from 24 cents.

Free cash flow also reached a record $124.9 million. That combination explains why investors are paying closer attention to margin recovery, execution consistency and the company’s ability to turn sales growth into stronger earnings power.

What Allegro Signals Say NowThe bottom line is balanced. Allegro has strong long-term drivers in electrification, AI infrastructure and robotics, but valuation, cyclicality and execution risk still matter.

The stock currently carries a Zacks Rank #2 (Buy), with a VGM Score of B, Growth Score of A and Momentum Score of A. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Rank points to favorable near-term estimate support, while the Style Scores help investors evaluate the stock across growth, momentum and blended characteristics over a similar one- to three-month framework.

Exchange-initiated listing reflects Curaleaf's growing market maturity, and expands hedging, income, and directional strategies available to investors

, /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced that exchange-traded options on the Company's subordinate voting shares (the "Shares") are expected to commence trading on the Montréal Exchange (the "MX"), Canada's derivatives exchange, on July 13, 2026, under the symbol "CURA".

"The listing of exchange-traded options on the Montréal Exchange reflects Curaleaf's market capitalization, trading depth and growing institutional relevance," said Boris Jordan, Chairman and CEO of Curaleaf. "Because the listing decision rests solely with the Exchange, we view it as independent recognition of the progress we have made as a public company. Listed options will give investors greater flexibility to hedge risk, pursue income strategies and express a view on Curaleaf's long-term growth—the same tools commonly available to investors in mature equity markets. We welcome the additional flexibility this listing provides investors."

The Company believes the listing will also increase liquidity and improve price discovery by attracting options traders, market makers and institutional investors whose strategies incorporate derivatives.

The decision to list options on a particular security is made solely by the Montréal Exchange based on its own eligibility criteria, including factors such as market capitalization, share price, and trading activity. The Company did not apply for, and does not control, the listing of options on its Shares.

Options listed by the MX are contracts between market participants and are not issued by the Company. The listing of options does not involve the issuance of any Shares or other securities of the Company, has no dilutive effect on shareholders, and does not result in any proceeds to the Company. No action is required by shareholders in connection with the commencement of options trading.

Investors seeking information about options on the Company's Shares, including available series, strike prices, and expiry dates, should consult the Montréal Exchange website at www.m-x.ca or contact their investment advisor. Options involve risk and are not suitable for all investors. Investors should read the disclosure document titled "The Characteristics and Risks of Listed Canadian Options," available from the Canadian Derivatives Clearing Corporation, before trading options.

About Curaleaf Holdings
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, Find, Dark Heart, and Anthem, provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is powered by a strong presence in all stages of the supply chain. Its unique distribution network throughout Europe, Canada and Australasia brings together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.

Forward Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans", "expects" or "proposed", "is expected", "intends", "anticipates", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the expected commencement of options trading on the Montréal Exchange, the expected commencement date thereof, and the potential effects of the availability of listed options on the Company's Shares, including with respect to trading liquidity, price discovery, risk management, investor access, and institutional engagement.  The commencement of options trading is subject to the discretion of the Montréal Exchange and may be delayed or not occur as anticipated. There can be no assurance that any of these potential effects will be realized, as trading activity in options and in Shares is determined by market participants and is outside the Company's control. Such forward-looking statements and information reflect management's current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matter described in this news release. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information about these assumptions and uncertainties is contained under "Risk Factors and Uncertainties" in the Company's latest annual information form filed on February 26, 2026, which is available under the Company's profile on SEDAR+ at www.sedarplus.ca, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved the content of this news release.

Investor Contact:
Curaleaf Holdings, Inc.
Camilo Lyon, Chief Investment Officer
[email protected]

Media Contact:
MATTIO Communications
[email protected]

SOURCE Curaleaf Holdings, Inc.

Key Takeaways Commercial title insurance continues to grow, supported by large data center, energy and industrial deals.AI-powered automation and technology investments are improving operating efficiency and expanding margins. FAF continues returning capital, with $248 million remaining for share repurchases. Shares of First American Financial Corporation (FAF - Free Report) have risen 20.8% in the past year, outperforming the industry’s growth of 6%. The stock closed at $70.26 on Thursday, near its 52-week high of $71.47, reflecting investor confidence.

The rally has been driven by strong operating performance, robust commercial title insurance activity and higher investment income. Continued technology investments, disciplined capital deployment and strength in the commercial title business are expected to support earnings growth. While the residential housing market remains weak due to elevated mortgage rates and affordability challenges, a gradual recovery in home purchase activity could provide a further upside.

1-Year Price Performance: FAF, RNR, AXS, NMIH & Industry
Image Source: Zacks Investment Research

Shares of some other insurers like RenaissanceRe Holdings Ltd. (RNR - Free Report) , NMI Holdings Inc. (NMIH - Free Report) and Axis Capital Holdings Limited (AXS - Free Report) have gained 31%, 8.2% and 16.8% respectively in the past year.

Average Target Price for FAF Suggests UpsideBased on short-term price targets offered by five analysts, the Zacks average price target is $85.80 per share. The average suggests a potential 22.5% upside from the last closing price.    

Image Source: Zacks Investment Research

FAF Shares Are AffordableDespite the rally, First American shares are trading at a discount to the industry. Its 12-month trailing price-to-book value of 1.30X is lower than the industry average of 1.47X. The insurer has a Value Score of A.

Image Source: Zacks Investment Research

Shares of RenaissanceRe, NMI Holdings and Axis Capital are also trading at a discount to the industry average.

FAF’s Growth Projection EncouragesThe Zacks Consensus Estimate for First American’s 2026 earnings per share (EPS) indicates a year-over-year increase of 11.6%. The consensus estimate for revenues is pegged at $7.9 billion, implying a year-over-year improvement of 6.4%.

The consensus estimate for 2027 EPS and revenues indicates an increase of 5.8% and 5.7%, respectively, from the corresponding 2026 estimates.

The expected long-term earnings growth rate is 15.2%, outperforming the industry average of 7.2%. FAF has a Growth Score of B.

Optimist Analyst Sentiment on FAFThe company has witnessed one upward earnings estimate revision for 2026 and 2027 over the past 60 days, against one movement in the opposite direction, respectively. Thus, the Zacks Consensus Estimate for 2026 and 2027 earnings has moved up 0.4% and 0.1%, respectively, in the past 60 days.

FAF’s Efficient Use of Shareholder CapitalFirst American’s trailing 12-month return on equity of 24% compared favorably with the industry’s 7.4%, reflecting the company’s efficiency in utilizing shareholders’ funds.

Key Drivers of FAF StockCommercial title insurance remains FAF's primary growth engine. The company continues to benefit from strong demand for large commercial transactions, particularly in data centers, energy and industrial projects. Higher transaction volumes and larger deal sizes have driven record commercial title revenue, and management expects 2026 to be another record year for the business, supported by a healthy pipeline of high-value transactions.

The company is deploying AI across its operations through platforms such as Endpoint and SEQUOIA, automating title decisioning and escrow workflows. These initiatives are expected to improve operating efficiency, expand margins and strengthen long-term earnings growth.

The title insurer remains focused on strengthening its product offerings, enhancing its core business, and expanding its valuation and data businesses. The expansion of title plant assets and the upgrade of technology solutions drive increased efficiency.

Higher investment income continues to support earnings growth. In the first quarter of 2026, investment income increased 12% year over year to $154 million. The company is benefiting from rising deposit balances, including commercial escrow, 1031 exchange and agent banking deposits, while optimizing its investment portfolio toward higher-yielding securities.

First American distributes wealth to shareholders via dividend hikes and share buybacks. The remaining $248 million under its share repurchase authorization provides flexibility for shareholder-friendly capital deployment. Its dividend yield and payout ratio are better than the industry average, making it an attractive pick for yield-seeking investors.

Risks for FAFElevated mortgage rates, affordability challenges and low housing inventory continue to pressure home purchase activity and title insurance revenues.

FAF's strong dependence on commercial title insurance also remains a risk. A slowdown in commercial real estate transactions could weigh on FAF's revenue growth and earnings.

ConclusionStrength in commercial business, rising investment income, Continued investments in technology and disciplined capital deployment should favor FAF’s results. Weak residential housing market and dependence on commercial title are headwinds

FAF’s a VGM Score of A instils confidence. Given impressive dividend history, solid growth projections and higher return on equity, it is wise to retain this Zacks Rank #3 (Hold) insurer. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here

Key Takeaways AJG expects 2026 organic growth of about 7% in Risk Management and around 5.5% in Brokerage. AJG made eight deals in first-quarter 2026 and has around 40 term sheets in the pipeline. Dividend growth and buyback programs support shareholder returns, though higher expenses remain a risk. Shares of Arthur J. Gallagher & Co. (AJG - Free Report) are trading at a discount compared with the Zacks Brokerage Insurance industry. Its forward price-to-book value of 2.74X is lower than the industry average of 3.49X, the Finance sector’s 4.34X and the Zacks S&P 500 composite’s 8.07X.

Shares of other insurers like Erie Indemnity Company (ERIE - Free Report) are trading at a multiple higher than the industry average, while Brown & Brown, Inc. (BRO - Free Report) and Willis Towers Watson Public Limited Company (WTW - Free Report) are trading at a discount.

Image Source: Zacks Investment Research

AJG Trading Above 50-Day and 200-Day Moving AveragesShares of Arthur J. Gallagher closed at $253.76 on July 9 and are trading above the 50-day and 200-day simple moving averages (SMA) of $214.37 and $239.18, respectively, indicating solid upward momentum. SMA is a widely used technical analysis tool to predict future price trends by analyzing historical price data.

Image Source: Zacks Investment Research

Shares of Arthur J. Gallagher have lost 18.6% in the past year compared with the industry’s decline of 26.5%.

The insurer has a market capitalization of $65.2 billion. The average volume of shares traded in the last three months was 1.9 million.

Image Source: Zacks Investment Research

AJG’s Growth Projection EncouragesThe Zacks Consensus Estimate for Arthur J. Gallagher’s 2026 earnings per share indicates a year-over-year increase of 23.7%. The consensus estimate for revenues is pegged at $16.76 billion, implying a year-over-year improvement of 21.6%. The consensus estimate for 2027 earnings per share and revenues indicates an increase of 11.7% and 9.2%, respectively, from the 2026 estimates.

Earnings of Arthur J. Gallagher grew 18.1% in the last five years, better than the industry average of 13.9%. The long-term earnings growth is expected to be 14.9%, better than the industry average of 13.6%.

Target Price Reflects Potential UpsideBased on short-term price targets offered by 20 analysts, the Zacks average price target is $269.25 per share. The average indicates a potential 4.9% upside from the last closing price.

Image Source: Zacks Investment Research

Factors Impacting AJGArthur J. Gallagher remains focused on generating both organic (particularly international) and inorganic growth and is, thus, tapping into growth opportunities worldwide. This, coupled with solid retention and improving renewal premiums across all major geographies and most product lines, bodes well for growth.

In the Risk Management segment, AJG expects about 7% organic growth for 2026. AJG expects the full-year adjusted EBITDAC margin to range from 21% to 22%, up slightly from December expectations. In the Brokerage segment, AJG expects organic growth of around 5.5% for 2026, with projected underlying margin expansion of 40-60 basis points.

AJG’s revenues are geographically diversified with strong domestic and international operations. International contributes about one-third of revenues. Given the number and size of its non-U.S. acquisitions, AJG expects international contributions to its total revenues to trend upward.

Its inorganic growth story is impressive. Revenue growth rates generally ranged from 5% to 15% for 2026 acquisitions. In the first quarter of 2026, AJG completed eight acquisitions with estimated annualized revenues of about $49 million. Looking at the pipeline, AJG has around 40 term sheets signed or being prepared, representing around $400 million of annualized revenues.

AJG’s Capital DeploymentA robust capital position over the years reflects its financial flexibility. Banking on its capital position, AJG distributes wealth to shareholders through dividend hikes and share repurchases. In the first quarter of 2026, the dividend was raised by 7.6%, witnessing a three-year CAGR (2020-2025) of 7.6%. Arthur J. Gallagher’s current dividend yield is 1.1% and has a $1.5 billion share buyback program in place.
Risk

Arthur J. Gallagher has been experiencing an increase in expenses due to higher compensation, depreciation, amortization and operating expenses that have been eroding margins.

Arthur J. Gallagher’s return on equity of 12.8% is lower than the industry average of 18.8%. This shows the company’s inefficiency in managing shareholders’ funds. Also, the debt level is significant, which raises interest payouts and results in low times interest earned.

ConclusionAJG continues to benefit from solid retention, improving renewal premiums and organic and inorganic growth. The Risk Management and Brokerage segments should continue to witness significant growth. A robust capital position over the years reflects its financial flexibility. Its impressive dividend history, as well as solid growth projections, are other positives.

Given the escalating expenses and unfavorable return on capital, it is better to stay cautious about this Zacks Rank #3 (Hold) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.